Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Erin Chamberlain"'
Autor:
Aditya Bardia, Sara Hurvitz, Michael F. Press, Lisa S. Wang, Nicholas P. McAndrew, David Chan, Vu Phan, Deborah Villa, Merry L. Tetef, Erin Chamberlain, Nihal Abdulla, Thomas Lomis, Laura M. Spring, Steven Applebaum, Shaker Dakhil, Brian DiCarlo, David D. Kim, Evangelia Kirimis, William E. Lawler, Aashini K. Master, Kelly McCann, Edwin Hayashi, Christine Kivork, James Chauv
Publikováno v:
Cancer Research. 83:GS2-03
Background: Although patients (pts) with hormone receptor-positive (HR+)/HER2-negative breast cancer (BC) frequently experience disease response to neoadjuvant therapy, fewer than 10% achieve a pathologic complete response (pCR) with standard chemoth
Autor:
Rhoda Akilapa, Hanadi Kazkaz, Marion Bartlett, Glenda Sobey, Harveer Cheema, Fleur S van Dijk, Neeti Ghali, Vivienne McConnell, Jessica Bowen, Angela F. Brady, Renarta Crookes, Joanna Brock, Anthony Vandersteen, F Michael Pope, Chloe Angwin, Claire Green, Diana Johnson, Duncan Baker, Erin Chamberlain
Publikováno v:
Genetics in Medicine. 22:1576-1582
Purpose Currently, 31 patients with classical-like EDS (clEDS) due to tenascin-X deficiency have been reported in the literature. We report on the clinical and molecular characteristics of 20 additional patients with clEDS to expand knowledge and to
Autor:
Sara A. Hurvitz, Lisa S. Wang, David Chan, Vu Phan, Thomas Lomis, Nicholas Patrick McAndrew, Laura Spring, Merry L. Tetef, Deborah Villa, Steven Applebaum, Erin Chamberlain, Shaker R. Dakhil, Brian Anthony DiCarlo, David D. Kim, Evangelia K. Kirimis, William E. Lawler, Aashini K. Master, Christine Kivork, James Chauv, Aditya Bardia
Publikováno v:
Journal of Clinical Oncology. 40:TPS623-TPS623
TPS623 Background: Although patients with hormone receptor-positive (HR+)/HER2-negative breast cancer (BC) frequently experience disease response to neoadjuvant therapy, fewer than 10% achieve a pathologic complete response (pCR) with standard chemot
Autor:
Meghan Ferguson, Kara Matheson, Ashley Warias, Katharina Kieser, Lauren Currie, Erin Chamberlain, Lynette S. Penney, Nicole Snow
Publikováno v:
Journal of genetic counselingREFERENCES. 30(5)
Women with pathogenic variants in BRCA1/2 have a significantly increased lifetime risk of breast and ovarian cancers. The availability of genetic testing to identify BRCA1/2 carriers is imperative to disease prevention and treatment. We evaluated the
Publikováno v:
Infection and Immunity
Pseudomonas aeruginosa is an opportunistic pathogen that causes chronic and life-threatening infections in immunocompromised patients. A better understanding of the role that innate immunity plays in the control of P. aeruginosa infection is crucial
Autor:
Katharina Kieser, Lynette S. Penney, Lauren Currie, Meghan Ferguson, Ashley Warias, Erin Chamberlain, Kara Matheson, Nicole Snow
Publikováno v:
Journal of Obstetrics and Gynaecology Canada. 41:736-737
Objectives With increasing importance of prompt access to genetic counseling and testing for women with epithelial ovarian cancer (EOC), we evaluated the efficacy of a new collaborative model of care in Nova Scotia between Medical Genetics and the Da
Autor:
Elitza S. Germanov, Eugene C. Butcher, Linnea Lora Veinotte, Brent Johnston, Erin Chamberlain, Robyn Cullen
Publikováno v:
Scopus-Elsevier
NK T (NKT) cells play important roles in the regulation of diverse immune responses. However, little is known about the mechanisms that regulate homeostasis and activation of these cells. Thymic NKT cells up-regulated the chemokine receptor CXCR6 fol
Publikováno v:
International Review of Hydrobiology. 92:656-665
Japanese knotweed (Fallopia japonica HOUTT. RONSE DECRANE) is a highly invasive exotic plant that forms monocultures in riparian areas, effectively reducing plant diversity. This change in riparian plant composition alters the allocthonous input of l
Publikováno v:
JAMA Internal Medicine. 175:1271
Autor:
Erin Chamberlain, Julie N. Graff
Publikováno v:
Core Evidence
Metastatic castration-resistant prostate cancer is the lethal form of cancer of the prostate. Five new agents that prolong survival in this group have emerged in the past 5 years, and sipuleucel-T is among them. Sipuleucel-T is the only immunotherapy